Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
type: Dataset
contact point: Organization
  fn: CCSD
keyword: sdvmhepunlife-sciences-q-biohuman-health-and-pathologyurology-and-nephrology
keyword: angiogenesis
keyword: sdvcanlife-sciences-q-biocancer
keyword: sdvsplife-sciences-q-biopharmaceutical-sciences
keyword: clear-cell-renal-cell-carcinoma
keyword: combinations
keyword: journal-articles
keyword: infoeu-reposemanticsarticle
keyword: anti-angiogenic-drugs
landing page: 0171-5216
description: International audience
issued: 2026-05-28T14:48:56.051238
language: en
modified: 2026-05-28T14:48:56.051244

test_moissonnage_selune
type: Agent

Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
type: Distribution
access URL: https://inserm.hal.science/inserm-00670441
format: HTML
issued: 2026-05-28T14:48:56.065195
modified: 2026-05-28T14:48:56.014646